600062 华润双鹤
已收盘 07-03 15:00:00
资讯
新帖
简况
华润双鹤(600062.SH)子公司黄体酮软胶囊获得药品注册证书
智通财经 · 17:24
华润双鹤(600062.SH)子公司黄体酮软胶囊获得药品注册证书
华润双鹤（600062）披露复方聚乙二醇(3350)电解质散获得药品注册证书的公告，7月1日股价上涨3.68%
证券之星 · 07-01 22:40
华润双鹤（600062）披露复方聚乙二醇(3350)电解质散获得药品注册证书的公告，7月1日股价上涨3.68%
华润双鹤(600062.SH)子公司丙戊酸钠原料药获得CEP证书
智通财经 · 07-01 17:28
华润双鹤(600062.SH)子公司丙戊酸钠原料药获得CEP证书
股市必读：华润双鹤（600062）6月29日董秘有最新回复
证券之星 · 06-30
股市必读：华润双鹤（600062）6月29日董秘有最新回复
6月29日华润双鹤涨6.86%，宝盈祥颐定期开放混合A基金重仓该股
证券之星 · 06-29
6月29日华润双鹤涨6.86%，宝盈祥颐定期开放混合A基金重仓该股
每周股票复盘：华润双鹤（600062）完成收购新百药业并纳入合并报表
证券之星 · 06-28
每周股票复盘：华润双鹤（600062）完成收购新百药业并纳入合并报表
6月26日华润双鹤创60日新低，宝盈祥颐定期开放混合A基金重仓该股
证券之星 · 06-26
6月26日华润双鹤创60日新低，宝盈祥颐定期开放混合A基金重仓该股
华润双鹤（600062）披露收购南京新百药业100%股权进展暨完成工商变更登记公告，6月25日股价下跌2.19%
证券之星 · 06-25
华润双鹤（600062）披露收购南京新百药业100%股权进展暨完成工商变更登记公告，6月25日股价下跌2.19%
6月23日华润双鹤发生1笔大宗交易 成交金额465万元
证券之星 · 06-23
6月23日华润双鹤发生1笔大宗交易 成交金额465万元
每周股票复盘：华润双鹤（600062）子公司三款药品获注册证书
证券之星 · 06-20
每周股票复盘：华润双鹤（600062）子公司三款药品获注册证书
华润双鹤(600062.SH)子公司部分产品获得药品注册证书
智通财经 · 06-16
华润双鹤(600062.SH)子公司部分产品获得药品注册证书
每周股票复盘：华润双鹤（600062）拟续聘毕马威为2026年度审计机构
证券之星 · 05-31
每周股票复盘：华润双鹤（600062）拟续聘毕马威为2026年度审计机构
华润双鹤（600062）披露2026年度审计机构续聘议案，5月29日股价上涨1.45%
证券之星 · 05-29
华润双鹤（600062）披露2026年度审计机构续聘议案，5月29日股价上涨1.45%
每周股票复盘：华润双鹤（600062）拟续聘毕马威为2026年审计机构
证券之星 · 05-24
每周股票复盘：华润双鹤（600062）拟续聘毕马威为2026年审计机构
华润双鹤（600062）披露续聘会计师事务所公告，5月18日股价下跌1.76%
证券之星 · 05-18
华润双鹤（600062）披露续聘会计师事务所公告，5月18日股价下跌1.76%
每周股票复盘：华润双鹤（600062）钠钾镁钙注射液获批
证券之星 · 05-10
每周股票复盘：华润双鹤（600062）钠钾镁钙注射液获批
华润双鹤(600062.SH)子公司钠钾镁钙注射用浓溶液获得药品注册证书
智通财经 · 05-08
华润双鹤(600062.SH)子公司钠钾镁钙注射用浓溶液获得药品注册证书
每周股票复盘：华润双鹤（600062）尼麦角林片获批丰富产品线
证券之星 · 05-02
每周股票复盘：华润双鹤（600062）尼麦角林片获批丰富产品线
华润双鹤（600062）披露全资子公司尼麦角林片获得药品注册证书，4月29日股价上涨0.45%
证券之星 · 04-29
华润双鹤（600062）披露全资子公司尼麦角林片获得药品注册证书，4月29日股价上涨0.45%
股市必读：华润双鹤一季报 - 第一季度单季净利润同比下降4.30%
证券之星 · 04-27
股市必读：华润双鹤一季报 - 第一季度单季净利润同比下降4.30%
公司概况
公司名称：
华润双鹤药业股份有限公司
所属行业：
医药制造业
上市日期：
1997-05-22
主营业务：
华润双鹤药业股份有限公司的主营业务是慢病业务、专科业务、输液业务、原料药业务。公司的主要产品是缬沙坦、氨氯地平、普瑞巴林、氨苯蝶啶、喷他佐辛、匹伐他汀、素钠、依诺肝素原料、辅酶Q10、S-Na盐。0号、压氏达、穗悦、贝奇灵、糖适平、卜可、冠爽、珂立苏、诺百益、小儿复方氨基酸注射液(19AA-I)、基础输液、BFS等产品获评中国化学制药行业各细分领域优秀产品品牌。
发行价格：
6.69
{"stockData":{"symbol":"600062","market":"SH","secType":"STK","nameCN":"华润双鹤","latestPrice":17.07,"timestamp":1783062000000,"preClose":16.75,"halted":0,"volume":10082640,"delay":0,"changeRate":0.0191,"floatShares":1038000000,"shares":1039000000,"eps":1.5648,"marketStatus":"已收盘","change":0.32,"latestTime":"07-03 15:00:00","open":16.76,"high":17.1,"low":16.71,"amount":170000000,"amplitude":0.0233,"askPrice":17.08,"askSize":644,"bidPrice":17.07,"bidSize":178,"shortable":0,"etf":0,"ttmEps":1.5648,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783301400000},"marketStatusCode":5,"adr":0,"adjPreClose":16.75,"symbolType":"stock","openAndCloseTimeList":[[1783042200000,1783049400000],[1783054800000,1783062000000]],"highLimit":18.43,"lowLimit":15.08,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1038582511,"isCdr":false,"pbRate":1.46,"roa":"--","peRate":10.908742,"roe":"4.08%","epsLYR":1.5949,"committee":-0.613856,"marketValue":17729000000,"turnoverRate":0.0097,"status":0,"floatMarketCap":17723000000},"requestUrl":"/m/hq/s/600062/wiki","defaultTab":"wiki","newsList":[{"id":"2648657427","title":"华润双鹤(600062.SH)子公司黄体酮软胶囊获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2648657427","media":"智通财经","labels":["productRelease"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648657427?lang=zh_cn&edition=full","pubTime":"2026-07-03 17:24","pubTimestamp":1783070653,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司全资子公司山西晋新双鹤药业有限责任公司收到了国家药品监督管理局颁发的黄体酮软胶囊《药品注册证书》。据悉，黄体酮软胶囊用于治疗由黄体酮缺乏引起的机能障碍：排卵机能障碍引起的月经失调;痛经及经前期综合征;出血(由纤维瘤等所致);绝经前紊乱;绝经(用于补充雌激素治疗)。本品也助于妊娠。在使用黄体酮进行治疗的所有适应症时，因黄体酮能引起诸如嗜睡，头晕目眩等不良反应时，可以用阴道给药代替口服给药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462945.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润双鹤(600062.SH)子公司黄体酮软胶囊获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0010","BK0028","BK0185","BK0188","BK0239","600062","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648488541","title":"华润双鹤（600062）披露复方聚乙二醇(3350)电解质散获得药品注册证书的公告，7月1日股价上涨3.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648488541","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648488541?lang=zh_cn&edition=full","pubTime":"2026-07-01 22:40","pubTimestamp":1782916824,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，华润双鹤报收于16.63元，较前一交易日上涨3.68%，最新总市值为172.72亿元。该股当日开盘16.04元，最高16.66元，最低15.84元，成交额达1.88亿元，换手率为1.11%。华润双鹤近日收到国家药品监督管理局颁发的复方聚乙二醇电解质散《药品注册证书》，批准该药品上市。该药品用于治疗1岁至11岁儿童慢性便秘及5岁至11岁儿童粪便嵌塞。截至公告日，累计研发投入493.77万元。目前国内已有23家企业获批该药品上市，2025年国内销售总额为1,976万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100043610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0010","600062","BK0175","BK0185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648519132","title":"华润双鹤(600062.SH)子公司丙戊酸钠原料药获得CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2648519132","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648519132?lang=zh_cn&edition=full","pubTime":"2026-07-01 17:28","pubTimestamp":1782898097,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司控股子公司华润双鹤湘中药业(湖南)有限公司收到了欧洲药品质量管理局(EDQM)签发的丙戊酸钠原料药欧洲药典适用性认证证书(简称“CEP证书”)。丙戊酸钠是一种用于治疗精神疾病的药物，主要用于治疗癫痫、躁狂症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461879.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0185","BK0175","BK0239","BK0028","BK0188","BK0010","600062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647930987","title":"股市必读：华润双鹤（600062）6月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2647930987","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647930987?lang=zh_cn&edition=full","pubTime":"2026-06-30 01:46","pubTimestamp":1782755175,"startTime":"0","endTime":"0","summary":"截至2026年6月29日收盘，华润双鹤报收于16.67元，上涨6.86%，换手率1.43%，成交量14.84万手，成交额2.4亿元。董秘最新回复投资者： 公司工业底盘菌项目是否已经进行了半导体封装、功率器件耐高温PA46的生产？目前暂无其他高纯二元胺和电子级二元醇产品生产规划。当日关注点交易信息汇总：6月29日主力资金净流入686.3万元，游资资金净流出2131.73万元，散户资金净流入1445.43万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000001075.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600062","BK0010","BK0175","BK0028","BK0185","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647324618","title":"6月29日华润双鹤涨6.86%，宝盈祥颐定期开放混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647324618","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647324618?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:28","pubTimestamp":1782721712,"startTime":"0","endTime":"0","summary":"证券之星消息，6月29日华润双鹤涨6.86%创60日新低，收盘报16.67元，换手率1.43%，成交量14.84万手，成交额2.4亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为宝盈基金的宝盈祥颐定期开放混合A。宝盈祥颐定期开放混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","600062","BK0239","BK0185","BK0010","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646736313","title":"每周股票复盘：华润双鹤（600062）完成收购新百药业并纳入合并报表","url":"https://stock-news.laohu8.com/highlight/detail?id=2646736313","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646736313?lang=zh_cn&edition=full","pubTime":"2026-06-28 02:44","pubTimestamp":1782585852,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，华润双鹤报收于15.6元，较上周的16.38元下跌4.76%。公司公告汇总：华润双鹤已支付50%股权转让款，新百药业完成工商变更登记，自2026年6月起纳入合并报表范围。公司公告汇总华润双鹤药业股份有限公司于2026年4月23日召开第十届董事会第十九次会议，审议通过收购南京新百药业有限公司100%股权的议案。2026年6月23日，博雅生物已完成对新百药业的资金归集解除并支付利息，相关应收账款余额为0元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800000723.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0239","BK0010","BK0028","BK0185","600062","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646790337","title":"6月26日华润双鹤创60日新低，宝盈祥颐定期开放混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646790337","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646790337?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:21","pubTimestamp":1782462062,"startTime":"0","endTime":"0","summary":"证券之星消息，6月26日华润双鹤创60日新低，收盘报15.6元，当日跌3.11%，换手率0.71%，成交量7.38万手，成交额1.16亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为宝盈基金的宝盈祥颐定期开放混合A。宝盈祥颐定期开放混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600029673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0185","BK0188","600062","BK0239","BK0010","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646780992","title":"华润双鹤（600062）披露收购南京新百药业100%股权进展暨完成工商变更登记公告，6月25日股价下跌2.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646780992","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646780992?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:33","pubTimestamp":1782397995,"startTime":"0","endTime":"0","summary":"截至2026年6月25日收盘，华润双鹤报收于16.1元，较前一交易日下跌2.19%，最新总市值为167.21亿元。该股当日开盘16.3元，最高16.3元，最低15.97元，成交额达1.13亿元，换手率为0.68%。近日，华润双鹤药业股份有限公司发布《关于收购南京新百药业有限公司100%股权进展暨完成工商变更登记的公告》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500044348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0175","BK0183","BK0114","BK0196","BK0188","BK0028","BK0070","BK0113","600062","BK0185","BK0093","BK0010","BK0209","600682","BK0060","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645887567","title":"6月23日华润双鹤发生1笔大宗交易 成交金额465万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2645887567","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645887567?lang=zh_cn&edition=full","pubTime":"2026-06-23 17:52","pubTimestamp":1782208361,"startTime":"0","endTime":"0","summary":"证券之星消息，6月23日华润双鹤发生大宗交易，交易数据如下：大宗交易成交价格15.5元，相对当日收盘价折价6.74%，成交30万股，成交金额465万元，买方营业部为民生证券股份有限公司北京第一分公司，卖方营业部为中泰证券股份有限公司杭州湖墅南路证券营业部。近三个月该股共发生1笔大宗交易，合计成交3000.0手，折价成交1笔。截至2026年6月23日收盘，华润双鹤报收于16.62元，上涨0.85%，换手率0.74%，成交量7.72万手，成交额1.29亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300031090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","600062","BK0185","BK0239","BK0188","BK0028","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644958063","title":"每周股票复盘：华润双鹤（600062）子公司三款药品获注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2644958063","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644958063?lang=zh_cn&edition=full","pubTime":"2026-06-20 02:07","pubTimestamp":1781892432,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，华润双鹤报收于16.38元，较上周的17.17元下跌4.6%。本周，华润双鹤6月15日盘中最高价报17.21元。本周关注点公司公告汇总：子公司华润赛科、晋新双鹤及双鹤湘中分别获得利格列汀二甲双胍片(Ⅱ)、黄体酮注射液(Ⅱ)和氢溴酸伏硫西汀片的《药品注册证书》。三款药品分别用于2型糖尿病、辅助生殖技术中黄体酮补充治疗及成人抑郁症。此次获批将丰富公司产品线，提升市场竞争力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000000551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0028","BK0239","BK0175","BK0188","600062","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643730475","title":"华润双鹤(600062.SH)子公司部分产品获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2643730475","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643730475?lang=zh_cn&edition=full","pubTime":"2026-06-16 17:01","pubTimestamp":1781600512,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司全资子公司华润赛科药业有限责任公司(简称“华润赛科”)、山西晋新双鹤药业有限责任公司(简称“晋新双鹤”)，控股子公司华润双鹤湘中药业(湖南)有限公司(简称“双鹤湘中”)分别收到了国家药监局颁发的利格列汀二甲双胍片(Ⅱ)、黄体酮注射液(Ⅱ)和氢溴酸伏硫西汀片《药品注册证书》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润双鹤(600062.SH)子公司部分产品获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0010","BK0175","BK0185","600062","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639760488","title":"每周股票复盘：华润双鹤（600062）拟续聘毕马威为2026年度审计机构","url":"https://stock-news.laohu8.com/highlight/detail?id=2639760488","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639760488?lang=zh_cn&edition=full","pubTime":"2026-05-31 02:35","pubTimestamp":1780166112,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，华润双鹤报收于16.74元，较上周的16.91元下跌1.01%。本周，华润双鹤5月27日盘中最高价报17.12元。5月28日盘中最低价报16.44元，股价触及近一年最低点。华润双鹤当前最新总市值173.86亿元，在化学制药板块市值排名28/150，在两市A股市值排名1227/5207。本周关注点公司公告汇总：拟续聘毕马威华振会计师事务所为公司2026年度审计机构，聘期一年。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100000643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0175","600062","BK0185","BK0188","BK0010","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639673155","title":"华润双鹤（600062）披露2026年度审计机构续聘议案，5月29日股价上涨1.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2639673155","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639673155?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:16","pubTimestamp":1780064184,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，华润双鹤报收于16.74元，较前一交易日上涨1.45%，最新总市值为173.86亿元。该股当日开盘16.5元，最高16.86元，最低16.45元，成交额达1.29亿元，换手率为0.75%。近日，华润双鹤药业股份有限公司发布2025年度股东会会议文件，拟续聘毕马威华振会计师事务所为公司2026年度审计机构，聘期一年，并提请股东会授权董事会决定2026年审计费用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900046220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0185","BK0239","BK0010","BK0188","600062","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637137381","title":"每周股票复盘：华润双鹤（600062）拟续聘毕马威为2026年审计机构","url":"https://stock-news.laohu8.com/highlight/detail?id=2637137381","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637137381?lang=zh_cn&edition=full","pubTime":"2026-05-24 02:05","pubTimestamp":1779559512,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，华润双鹤报收于16.91元，较上周的17.58元下跌3.81%。本周关注点公司公告汇总：华润双鹤拟续聘毕马威华振会计师事务所为2026年度审计机构，审计费用为240万元，较上年增长12%。两项议案将提交2025年度股东会审议。华润双鹤将于2026年6月8日召开2025年度股东会，采用现场与网络投票结合方式，股权登记日为2026年6月1日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400000425.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600062","BK0028","BK0188","BK0175","BK0185","BK0010","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636007171","title":"华润双鹤（600062）披露续聘会计师事务所公告，5月18日股价下跌1.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636007171","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636007171?lang=zh_cn&edition=full","pubTime":"2026-05-18 22:15","pubTimestamp":1779113720,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，华润双鹤报收于17.27元，较前一交易日下跌1.76%，最新总市值为179.36亿元。该股当日开盘17.5元，最高17.56元，最低17.23元，成交额达1.06亿元，换手率为0.59%。近日，华润双鹤药业股份有限公司发布《关于续聘会计师事务所公告》。公告显示，公司拟续聘毕马威华振会计师事务所为2026年度审计机构。审计费用为240万元，较上年增长12%。该事项尚需提交公司2025年度股东会审议通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800037322.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0010","BK0239","BK0175","BK0185","600062","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634123114","title":"每周股票复盘：华润双鹤（600062）钠钾镁钙注射液获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2634123114","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634123114?lang=zh_cn&edition=full","pubTime":"2026-05-10 03:13","pubTimestamp":1778353990,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，华润双鹤报收于17.94元，较上周的17.85元上涨0.5%。本周，华润双鹤5月8日盘中最高价报18.08元。华润双鹤当前最新总市值186.32亿元，在化学制药板块市值排名25/150，在两市A股市值排名1186/5200。安徽双鹤于2023年6月启动研发，2024年11月提交上市申请并获受理，2026年4月29日获批，视同通过一致性评价。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000001270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0028","BK0175","BK0239","600062","BK0188","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633436007","title":"华润双鹤(600062.SH)子公司钠钾镁钙注射用浓溶液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2633436007","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633436007?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:13","pubTimestamp":1778231581,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司全资子公司安徽双鹤药业有限责任公司(简称“安徽双鹤”)收到了国家药品监督管理局颁发的钠钾镁钙注射用浓溶液《药品注册证书》。钠钾镁钙注射用浓溶液用于通过中心静脉输注含浓葡萄糖或氨基酸的溶液时的电解质补充，以维持成人患者的电解质动态平衡。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润双鹤(600062.SH)子公司钠钾镁钙注射用浓溶液获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0010","600062","BK0188","BK0185","BK0175","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632647061","title":"每周股票复盘：华润双鹤（600062）尼麦角林片获批丰富产品线","url":"https://stock-news.laohu8.com/highlight/detail?id=2632647061","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632647061?lang=zh_cn&edition=full","pubTime":"2026-05-02 04:26","pubTimestamp":1777667171,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，华润双鹤报收于17.85元，较上周的17.89元下跌0.22%。本周关注点来自公司公告汇总：尼麦角林片获药品注册证书，视同通过一致性评价。公司公告汇总华润双鹤全资子公司华润双鹤利民药业(济南)有限公司收到国家药监局颁发的尼麦角林片《药品注册证书》，规格为30mg，注册分类为化学药品3类，视同通过一致性评价。此次获批有助于丰富公司产品线，提升市场竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200002737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0188","600062","BK0239","BK0010","BK0185","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631152825","title":"华润双鹤（600062）披露全资子公司尼麦角林片获得药品注册证书，4月29日股价上涨0.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631152825","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631152825?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:47","pubTimestamp":1777463273,"startTime":"0","endTime":"0","summary":"截至2026年4月29日收盘，华润双鹤报收于17.96元，较前一交易日上涨0.45%，最新总市值为186.53亿元。华润双鹤于2026年4月29日披露公告，其全资子公司华润双鹤利民药业（济南）有限公司近日收到国家药监局颁发的尼麦角林片《药品注册证书》，规格为30mg，注册分类为化学药品3类，视同通过一致性评价。双鹤利民于2022年启动研发，2024年11月提交上市申请并获受理，2026年4月21日获批。截至公告日，累计研发投入1,111.74万元。目前国内已有16家企业获批该药品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900060581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0028","BK0239","BK0175","BK0188","600062","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630334390","title":"股市必读：华润双鹤一季报 - 第一季度单季净利润同比下降4.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630334390","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630334390?lang=zh_cn&edition=full","pubTime":"2026-04-27 06:54","pubTimestamp":1777244052,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，华润双鹤报收于17.89元，下跌0.89%，换手率0.67%，成交量7.0万手，成交额1.26亿元。股本股东变化股东户数变动近日华润双鹤披露，截至2026年3月31日公司股东户数为5.5万户，较2月28日增加339.0户，增幅为0.62%。业绩披露要点财务报告华润双鹤2026年一季报显示，一季度公司主营收入28.07亿元，同比下降8.84%；归母净利润4.85亿元，同比下降4.3%；扣非净利润4.69亿元，同比下降3.51%；负债率27.79%，投资收益5830.67万元，财务费用1269.94万元，毛利率59.03%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700006880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600062"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783078847130,"stockEarnings":[{"period":"1week","weight":0.0404},{"period":"1month","weight":-0.0124},{"period":"3month","weight":-0.098},{"period":"6month","weight":-0.0842},{"period":"1year","weight":-0.0772},{"period":"ytd","weight":-0.0842}],"compareEarnings":[{"period":"1week","weight":-0.0222},{"period":"1month","weight":-0.0113},{"period":"3month","weight":0.0384},{"period":"6month","weight":0.0151},{"period":"1year","weight":0.1662},{"period":"ytd","weight":0.0151}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华润双鹤药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"54972人(较上一季度增加0.62%)","perCapita":"18886股","listingDate":"1997-05-22","address":"北京市朝阳区望京利泽东二路1号","registeredCapital":"103858万元","survey":" 华润双鹤药业股份有限公司的主营业务是慢病业务、专科业务、输液业务、原料药业务。公司的主要产品是缬沙坦、氨氯地平、普瑞巴林、氨苯蝶啶、喷他佐辛、匹伐他汀、素钠、依诺肝素原料、辅酶Q10、S-Na盐。0号、压氏达、穗悦、贝奇灵、糖适平、卜可、冠爽、珂立苏、诺百益、小儿复方氨基酸注射液(19AA-I)、基础输液、BFS等产品获评中国化学制药行业各细分领域优秀产品品牌。","listedPrice":6.69},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华润双鹤(600062)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华润双鹤(600062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华润双鹤,600062,华润双鹤股票,华润双鹤股票老虎,华润双鹤股票老虎国际,华润双鹤行情,华润双鹤股票行情,华润双鹤股价,华润双鹤股市,华润双鹤股票价格,华润双鹤股票交易,华润双鹤股票购买,华润双鹤股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华润双鹤(600062)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华润双鹤(600062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}